April 1, 2025 08:17 PM EDTUpdated 09:00 AM

Judge orders HHS, other agencies to 'undo' probationary worker firings

Alexis Kramer

Deputy Editor

The HHS and other federal agencies must reverse the terminations of probationary government workers that were fired in the states challenging the cuts, under a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Judge orders HHS, other agencies to 'undo' probationary worker firings

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

Corrected: Trump's broad tariffs could mark a 'double whammy' for pharma after FDA cuts

Day after mass FDA firings, new commissioner addresses remaining staff, focusing on 'MAHA' vision

FDA cuts stir buyer’s remorse for some biopharma leaders, once excited by Trump

Q&A: John Crowley warns biotech is 'dangerously close' to breaking, as tariff threat, markets batter industry

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Judge or­ders HHS, oth­er agen­cies to 'un­do' pro­ba­tion­ary work­er fir­ings

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

Cor­rect­ed: Trump's broad tar­iffs could mark a 'dou­ble wham­my' for phar­ma af­ter FDA cuts

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Judge orders HHS, other agencies to 'undo' probationary worker firings

Corrected: Trump's broad tariffs could mark a 'double whammy' for pharma after FDA cuts

Day after mass FDA firings, new commissioner addresses remaining staff, focusing on 'MAHA' vision

FDA cuts stir buyer’s remorse for some biopharma leaders, once excited by Trump

Q&A: John Crowley warns biotech is 'dangerously close' to breaking, as tariff threat, markets batter industry

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO